Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy
- 21 March 2013
- journal article
- review article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 368 (12), 1131-1139
- https://doi.org/10.1056/nejmct1210890
Abstract
A woman receives a diagnosis of diffuse large B-cell lymphoma; a standard chemotherapy regimen is recommended. Use of prophylactic granulocyte CSF is considered. G-CSF stimulates proliferation of neutrophil progenitors and release of mature neutrophils from bone marrow.Keywords
This publication has 42 references indexed in Scilit:
- Comparison of Pegfilgrastim Prescribing Practice to National Guidelines at a University Hospital Outpatient Oncology ClinicJournal of Oncology Practice, 2013
- Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysisBMC Cancer, 2011
- Use of Colony-Stimulating Factors With Chemotherapy: Opportunities for Cost Savings and Improved OutcomesJNCI Journal of the National Cancer Institute, 2011
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- Congenital neutropenia: diagnosis, molecular bases and patient managementOrphanet Journal of Rare Diseases, 2011
- Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non–Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II StudiesJournal of Oncology Practice, 2010
- Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donorsBlood, 2009
- Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin’s LymphomaOnkologie, 2009
- 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineJournal of Clinical Oncology, 2006
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003